RESEARCH ON THE RANGE OF ANTI-PARKINSON'S DRUGS ON THE PHARMACEUTICAL MARKET OF UKRAINE
DOI:
https://doi.org/10.32782/health-2026.1.22Keywords:
Parkinson's disease, anti-Parkinson's drugs, pharmaceutical market, assortment, active pharmaceutical ingredientAbstract
The article presents the results of marketing research on the assortment portfolio of antiparkinsonian drugs on the pharmaceutical market of Ukraine, taking into account anatomical-therapeutic-chemical classification, release forms, manufacturing countries and manufacturing enterprises. The research was carried out using official sources of information, the data from which were studied, structured and systematized using statistical, logical and graphical methods. As a result of the analysis, it was found that as of February 2026, group N04 “Antiparkinson`s drugs” on the pharmaceutical market of Ukraine has 93 trade names (TN) of drugs. During the segmentation of the market for the studied group of drugs by country of manufacture, it was found that foreign drugs are more widely represented on the Ukrainian pharmaceutical market (76%). Among them, the largest number of medicinal products were registered from manufacturers in Slovenia (14 TN), India (12 TN), Germany (10 TN), Finland (9 TN), and Greece (8 TN). In Ukraine, only 4 pharmaceutical companies produce anti-Parkinsonian drugs, among which the leader is Pharma Start LLC with a share of 50% of the total number of trade names of domestic production. It was found that on the pharmaceutical market of Ukraine, antiparkinsonian drugs are presented in three dosage forms, with the majority of drugs (93.5% of the studied group) being produced in solid dosage forms, of which only one is in the form of capsules. In the structure of tableted medicines, traditional release drugs (79.1%) quantitatively prevail over drugs with prolonged action. At the same time, in the assortment of 22 domestic tableted medicines, only one is presented in the form of prolonged release tablets
References
Mantri S., Ghilardi M. F., Lessard N., et al. Proceedings of the world summit on parkinson's disease. NPJ Parkinsons Dis. 2025. № 11(1). P. 293. https://doi.org/10.1038/s41531-025-01123-8
Tolosa E., Garrido A., Schol, S. W., Poewe W. Challenges in the diagnosis of Parkinson's disease. The Lancet. Neurology. 2021. № 20(5). P. 385–397. https://doi.org/10.1016/S1474-4422(21)00030-2
Su D., Cui Y., He C., Yin P., Bai R., Zhu J., Lam J. S. T., Zhang J., Yan R., Zheng X., Wu J., Zhao D., Wang A., Zhou M., Feng T.. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ (Clinical research ed.). 2025. № 388. e080952. https://doi.org/10.1136/bmj-2024-080952
Radad K., Moldzio R., Krewenka C., Kranner B., Rausch W.D. Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation. Explor Neuroprot Ther. 2023. № 3. P. 24–46. https://doi.org/10.37349/ent.2023.00036
Kulcsarova K., Skorvanek M., Postuma R. B., Berg D. Defining Parkinson's Disease: Past and Future. Journal of Parkinson's disease. 2024. №14(s2). P. 257–271. https://doi.org/10.3233/JPD-230411V
Удовицький В. В., Бессарабов В. І. Розроблення та валідація спектрофотометричної методики визначення швидкості окиснення дофаміну в модельній хімічній системі. Health & Education. 2024. №3. C. 138-146. https://doi.org/10.32782/health-2024.3.16
Zhou M., Xu K., Ge J., Luo X., Wu M., Wang N., Zeng J. Targeting Ferroptosis in Parkinson's Disease: Mechanisms and Emerging Therapeutic Strategies. International journal of molecular sciences. 2024. № 25(23). P. 13042. https://doi.org/10.3390/ijms252313042
Khan, M. S. Nasiripour S., Bopassa J. C. Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review. International journal of molecular sciences. 2025. № 26(13). P. 6416. https://doi.org/10.3390/ijms26136416
Kerstens R., Joyce P. The Gut Microbiome as a Catalyst and Emerging Therapeutic Target for Parkinson's Disease: A Comprehensive Update. Biomedicines. 2024. №12(8). P. 1738. https://doi.org/10.3390/biomedicines12081738
Voruz P., Guérin D., Péron J. A. Impact of motor symptom asymmetry on non-motor outcomes in Parkinson's disease:
a systematic review. NPJ Parkinson's disease. 2025. № 11(1). P. 188. https://doi.org/10.1038/s41531-025-01046-4
Kurihara K., Nakagawa R., Ishido M., Yoshinaga Y., Watanabe J., Hayashi Y., Mishima T., Fujioka S., Tsuboi Y. Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: The Japanese Quality-of-Life Survey of Parkinson Disease (JAQPAD) study. Journal of the neurological sciences. 2020. №419, P. 117172. https://doi.org/10.1016/j.jns.2020.117172
Duart C., Souza E.B.d., Dias-Pinto J.R., Araldi R.P. Parkinson’s Disease: From Metabolism to Genetics-A Comprehensive Review. Curr. Issues Mol. Biol. 2026. № 48. P. 254. https://doi.org/10.3390/cimb48030254
Державний реєстр лікарських засобів. URL: http://www.drlz.com.ua (Дата звернення: 02.02.2026 р.)
Спеціалізоване медичне інтернет-видання для лікарів, провізорів, фармацевтів, студентів медичних і фармацевтичних вузів «Компендіум». URL: https://compendium.com.ua (Дата звернення: 02.02.2026 р.)
Смішко Р. О., Лижнюк В. В. Дослідження асортименту антигістамінних лікарських засобів на фармацевтичному ринку України. Health & Education. 2024. №3. С. 129-137. https://doi.org/10.32782/health-2024.3.15
